NewGenIvf (NIVF) Liabilities and Shareholders Equity (2022 - 2025)

NewGenIvf has disclosed Liabilities and Shareholders Equity across 4 years of filings, most recently posting $32.7 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity rose 814.62% year-over-year to $32.7 million; the TTM figure through Dec 2025 stood at $35558.4 billion (up 324151204.68% YoY), while the FY2025 annual figure was $32.7 million, up 814.62% from the prior year.
• Liabilities and Shareholders Equity retreated to $32.7 million in Q4 2025, from $35558.4 billion in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for NIVF reached as high as $35558.4 billion in Q3 2025 and fell as low as $2.9 million in Q4 2022.
• The 4-year median for Liabilities and Shareholders Equity is $9.7 million (2023), against an average of $5926.4 billion.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity decreased 20.26% — and 2025, when it surged 814.62%.
• A 4-year view of Liabilities and Shareholders Equity shows it stood at $2.9 million in 2022, then jumped by 54.46% to $4.5 million in 2023, then declined by 20.26% to $3.6 million in 2024, then surged by 814.62% to $32.7 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $32.7 million, $35558.4 billion, and $14.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.